FIG. 1A



Invasive-Disease-Free Survival (%)
100
80
60
40
20
0
93.3
89.2
85.9
88.4
81.5
77.1
Difference: 3-year IDFS rate
8.8% (95% CI, 4.5% to 13.0%)
Stratified hazard ratio 0.58 (99.5% CI, 0.41 to 0.82); P<0.0001
0 6 12 18 24 30 36 42
Time Since Randomization (Months)
No. at Risk
Olaparib 921 820 737 607 477 361 276 183
Placebo 915 807 732 585 452 353 256 173
Olaparib (106 events)
Placebo (178 events)

FIG. 1B



Distant-Disease-Free Survival (%)
100
80
60
40
20
0
94.3
90.0
87.5
90.2
83.9
80.4
Difference: 3-year DDFS rate
7.1% (95% CI, 3.0% to 11.1%)
Stratified hazard ratio 0.57 (99.5% CI, 0.39 to 0.83); P<0.0001
0 6 12 18 24 30 36 42
Time Since Randomization (Months)
No. at Risk
Olaparib 921 823 744 612 479 364 279 187
Placebo 915 817 742 594 461 359 263 179
Olaparib (89 events)
Placebo (152 events)

FIG. 1C



98.1
96.9
94.8
92.3
92.0
88.3
100
80
60
40
20
0
Overall Survival (%)
Difference: 3-year overall suvival rate
3.7% (95% CI, 0.3% to 7.1%)
Stratified hazard ratio 0.68 (99% CI, 0.44 to 1.05); P=0.024
0 6 12 18 24 30 36 42
No. at Risk
Time Since Randomization (Months)
Olaparib 921 856 801 659 531 400 310 205
Placebo 915 865 801 659 516 397 292 199
Olaparib (59 deaths)
Placebo (86 deaths)

FIG. 2



Subgroup
No. of patients with an Invasive-disease Event/ Total No.
Olaparib Placebo
Stratified hazard Ratio with 95% CI for Invasive-disease-free Survival
3-year Invasive-disease-free Survival Rate
Olaparib Placebo
All patients 106 / 921 178 / 915 0.581 (0.455-0.737) 85.9% 77.1%
Prior Chemotherapy
Neoadjuvant 70 / 460 117 / 460 0.555 (0.411-0.745) 82.5% 68.0%
Adjuvant 36 / 461 61 / 455 0.601 (0.394-0.901) 89.3% 85.4%
Prior Platinum-based Chemotherapy
Yes 34 / 247 43 / 239 0.773 (0.490-1.209) 82.0% 77.0%
No 72 / 674 135 / 676 0.520 (0.389-0.689) 87.3% 77.1%
Hormone Receptor Status
HR+/HER2- 19 / 168 25 / 157 0.701 (0.381-1.268) 83.5% 77.2%
TNBC 87 / 751 153 / 758 0.563 (0.431-0.730) 86.1% 76.9%
BRCA
BRCA1 70 / 558 126 / 558 0.524 (0.389-0.699) 85.0% 73.4%
BRCA2 22 / 230 38 / 209 0.515 (0.300-0.862) 88.6% 78.0%
BRCA1 and BRCA2 0 / 1 0 / 3 NC NC NC
Hormone Receptor Status by prior Chemotharopy
HR+/HER2-/NACT 13 / 104 20 / 92 0.521 (0.253-1.036) 86.0% 67.0%
HR+/HER2-/ACT 6 / 64 5 / 65 1.357 (0.409-4.710) 76.4% 89.3%
TNBC, NACT 57 / 354 97 / 368 0.571 (0.410-0.789) 81.4% 67.7%
TNBC,ACT 30 / 397 56 / 390 0.537 (0.341-0.830) 90.3% 84.8%
Prior Platinum-based Chemotherapy by Prior Chemotherapy
Yes, NACT 26 / 169 39 / 169 0.657 (0.396-1.073) 81.8% 70.1%
Yes, ACT 8 / 78 4 / 70 NC NC NC
No, NACT 44 / 291 78 / 291 0.507 (0.348-0.730) 83.1% 66.8%
No, ACT 28 / 383 57 / 385 0.505 (0.317-0.787) 90.4% 84.2%
CPS+EG Score NACT
CPS+EG Score of 2, 3, or 4 55 / 398 96 / 387 0.511 (0.365-0.709) 84.3% 68.9%
CPS+EG Score of 5 of 6 11 / 22 10 / 15 0.440 (0.185-1.060) 50.0% 17.9%
Primary Database
Breast International Group 95 / 810 160 / 806 0.583 (0.451-0.749) 86.0% 76.7%
NRG Oncology (United States) 11 / 111 18 / 109 0.566 (0.259-1.182) 85.0% 80.6%
0.25 0.50 0.75 1.00 1.25
Favors Olaparib Favors Placebo

FIG. 3

(Figure S5 as filed)




FIG. 4

(Figure S6 as filed)

